Calculus Capital
Calculus Capital is a London-based venture capital and private equity firm focused on established and mature small and medium-sized UK companies. It targets growth and expansion investments, management buyouts or buy-ins, acquisitions, and financing for generational change, as well as pre-IPO finance and growth capital across various sectors including media, energy, software and services, healthcare, manufacturing, and transportation. The firm typically invests between £2 million and £5 million in companies with positive EBITDA and annual sales of up to £50 million, and it commonly takes a board seat. Investments are generally held for about four to five years. Founded in 1999, Calculus Capital operates from London and concentrates on United Kingdom-based opportunities rather than startups or overseas ventures.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Scotland
Invizius
Venture Round in 2024
Invizius is a medical technology company focused on improving outcomes in extracorporeal blood treatments. It develops H-Guard, a hemocompatible coating designed to prevent foreign body reactions in the blood at the point of contact with medical devices used in dialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation. By reducing inflammatory and thrombotic complications associated with long-term dialysis and other extracorporeal circuits, Invizius aims to lower cardiovascular risk and improve patient safety during kidney replacement therapies and related procedures. Based in Edinburgh, United Kingdom, the company was established in 2018 and pursues additional applications in inflammatory and kidney-related conditions through its technology platform.
Invizius
Series A in 2021
Invizius is a medical technology company focused on improving outcomes in extracorporeal blood treatments. It develops H-Guard, a hemocompatible coating designed to prevent foreign body reactions in the blood at the point of contact with medical devices used in dialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation. By reducing inflammatory and thrombotic complications associated with long-term dialysis and other extracorporeal circuits, Invizius aims to lower cardiovascular risk and improve patient safety during kidney replacement therapies and related procedures. Based in Edinburgh, United Kingdom, the company was established in 2018 and pursues additional applications in inflammatory and kidney-related conditions through its technology platform.
Synpromics
Venture Round in 2017
Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
Synpromics
Venture Round in 2015
Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.